How did TFFP reduce operating expenses recently?

TFF Pharmaceuticals (TFFP) has reduced its operating expenses recently through strategic adjustments in resource allocation and cost management. Here's a detailed analysis: 1. **Decrease in R&D Expenses**: TFFP decreased R&D expenses by 12% year-over-year to $3.6 million. This reduction was primarily due to lowered manufacturing costs. However, this was offset by increased clinical and preclinical expenses. The company's focus has shifted towards advancing clinical trials over manufacturing, indicating a prioritization of high-impact areas. 2. **Decrease in G&A Expenses**: TFFP also decreased G&A expenses by 22% to $2.4 million. This reduction was mainly attributed to cost savings in compensation, market research, and insurance. The company's improved financial management and efficiency are evident, as the net loss was reduced to $5.7 million, down from $7.1 million in the previous year. 3. **Prioritization of Resource Allocation**: TFFP's financial performance in Q1 2024 reflects a strategic focus on allocating resources to high-potential areas. The company's ability to secure $6 million in new financing post-quarter close indicates strong investor confidence and provides essential liquidity for ongoing clinical trials and operations. In summary, TFFP has reduced its operating expenses by decreasing R&D and G&A costs through strategic resource allocation and cost management.